We previously identified a systemic metabolic defect associated with early weight loss in patients with Huntington's disease (HD), suggesting a lack of substrates for the Krebs cycle. Dietary anaplerotic therapy with triheptanoin is used in clinical trials to promote energy production in patients with peripheral and brain Krebs cycle deficit, as its metabolites -C5 ketone bodiescross the blood-brain barrier. We conducted a short-term clinical trial in six HD patients (UHDRS (Unified Huntington Disease Rating Scale)¼33±13, 15-49) to monitor the tolerability of triheptanoin. We also assessed peripheral markers of short-term efficacy that were shown to be altered in the early stages of HD, that is, low serum IGF1 and 31 P-NMR spectroscopy (NMRS) in muscle. At baseline, 31 P-NMRS displayed two patients with end-exercise muscle acidosis despite a low work output. On day 2, the introduction of triheptanoin was well tolerated in all patients, and in particular, there was no evidence of mitochondrial overload from triheptanoin-derived metabolites. After 4 days of triheptanoin-enriched diet, muscle pH regulation was normalized in the two patients with pretreatment metabolic abnormalities. A significant increase in serum IGF1 was also observed in all patients (205±60 ng/ml versus 246±68 ng/ml, P¼0.010). This study provides a rationale for extending our anaplerotic approach with triheptanoin in HD.
INTRODUCTION
Huntington's disease (HD) is an inherited severely disabling disorder without curative or preventive treatment. We showed that early weight loss in HD is associated with a systemic metabolic defect, and that branched-chain amino-acid (BCAA) levels can be used as a biomarker, indicative of disease onset and early progression. 1 Levels of IGF1, which are regulated by BCAA, were also significantly lower in the HD group. 1 The decrease in plasma BCAA observed in our HD group suggested the activation of a compensatory mechanism to provide energy substrates to the Krebs cycle, as described in cachexia-producing illnesses. 2 Similarly, dietary compounds such as triheptanoin have been used in human therapeutic trials for their ability to refill the pools of intermediates of the Krebs cycle, a key energetic process known as anaplerosis. 3 Owing to additional evidence for triheptanoin metabolites to cross the blood-brain barrier, 4 anaplerotic therapies represent promising molecules for reversing the energy deficit observed in both the brain and the periphery in HD patients. On the basis of the hypothesis that there is a need for Krebs cycle energy substrates in HD, we conducted a pilot study using a dietary anaplerotic approach to assess safety and short-term metabolic correction.
METHODS

Study design
We included six HD patients with abnormal CAG repeat expansions (mean¼46 ± 3) in the HTT gene with a mild-to-moderate disease, measured by the clinical scale UHDRS (Unified Huntington Disease Rating Scale) of 33±13 (Table 1 ). All participants were enrolled in a clinical protocol promoted by INSERM (COS 07-26, http://bir.inserm.fr), and approved by the local ethics committee. Written informed consent was obtained for all participants.
On the screening day -B1 month before the therapeutic trial -motor dysfunction was evaluated with the UHDRS, and each HD participant underwent 31 P-NMRS testing in muscle. The six HD patients were asked to fill an opened-ended questionnaire during three consecutive days, so that the dietician could determine their caloric intake and devise daily menus ensuring that triheptanoin oil provides 40% of an isocaloric diet, as established previously. 3, 4 At day 1, the six HD participants were hospitalized and height and weight were recorded to calculate the body mass index (BMI). Blood and urine samples were collected after an overnight fast for standard analyses, as well as plasma acylcarnitines, amino acids and ketone bodies, serum IGF1 and urine organic acids, as described previously. 4 At day 2, HD patients ingested the first doses of triheptanoin (1 g/kg per day divided in four meals). Repeated blood samples were collected before and, sequentially, after the first meal (30, 60, 90, 120 and 180 min after triheptanoin ingestion) for assessment of acylcarnitines profile, amino acids and ketone bodies. Urine samples were collected before and after the first ingestion of triheptanoin (90 and 180 min) for analyses of organic acids. During the next 3 days, HD participants kept consuming an isocaloric diet enriched with triheptanoin (1 g/kg per day). At day 5, standard analyses were repeated for fasting as well as plasma acylcarnitines, amino acids and ketone bodies, serum IGF1 and urine organic acids. UHDRS scoring was performed and muscle 31 P-NMRS was repeated. In view of the low risks to subjects participating in this protocol, continuous and close monitoring by the principal investigator was performed on an ongoing basis during the days the patients were taking triheptanoin -almost all triheptanoin-derived metabolites being used 3-4 h after its administration. 4 31 P-NMR spectroscopy in muscle NMR was carried out as described previously. 5 Data were analyzed semiautomatically to provide perfusion time course, PCr rephosphorylation time constant (TPCr) and end-exercise acidosis level (pH). The intensity of exercise (W/S) was determined by correcting work output (W, in Joules) developed during exercise to calf muscle area section (S, in cm 2 ).
Statistics
Data are expressed as mean ± SEM. Paired t-tests (SPSS, Chicago, IL, USA) were used to compare the values of plasma acylcarnitines, serum IGF1 and UHDRS before and after triheptanoin.
RESULTS
Patients' BMI ranged from 19 to 25 kg/cm 2 . There was no correlation between CAG repeats and metabolic measurement at baseline, except for an inverse correlation with plasma glutamine (Po0.001).
All patients tolerated the treatment well and no adverse event was monitored during the trial and beyond. As a result of feeding triheptanoin, urinary excretion of derivatives of heptanoate oxidation were detected -pimelate, 6-hydroxyheptanoate, 3-hydroxypentanoate (BHP), 3-ketopentanoate (BKP), 3-hydroxypropionate and methylcitrate -but there was no evidence of mitochondrial overload from triheptanoin-derived metabolites. Among plasma triheptanoinderived metabolites, there was no substantial increase in either pentanoylcarnitine (C5) or heptanoylcarnitine (C7) (data not shown) but propionylcarnitine (C3) increased significantly in all patients (Table 1) , indicating complete b-oxidation of heptanoate to propionyl-CoA. Substantial increases of C5 ketone bodies were observed after meal and triheptanoin administration (data not shown), with BHP to BKP ratios between 2.1 and 2.8. Plasma BCAA levels initially decreased after triheptanoin administration and then returned to their baseline levels on day 5 (data not shown). There was no significant change in UHDRS scores before and after triheptanoin (Table 1) . There was no correlation between CAG repeats and the levels of triheptanoin metabolites (data not shown).
During plantar flexion dynamic 31 P-NMRS, all HD patients presented with a work output about two-to four-fold lower (Supplementary Table) than that seen in healthy individuals -W/S¼34.96±16.35 J/cm 2 , n¼7. Measurements of intramuscular pH showed that two patients (P5 and P6) presented with end-exercise muscle acidosis -pH at 6.72 and 6.84, Figure 1 - Figure 1 End-exercise pH before (1) and after (2) triheptanoin in six patients with Huntington's disease (P1-P6). We observed normalization of the pH in the two patients (P5 and P6) with pretreatment metabolic abnormalities. Table) . Creatine rephosphorylation time constant was also increased in these two patients -tPCr of 63.1 and 52.5 s, respectively -but turned out to be normal when corrected for pH. 6 It must be noted that patient 5 had lower BMI (that is, 19 kg/cm 2 ), whereas patient 6 had the higher UHDRS score (that is, 49 kg/cm 2 ). Remarkably, after 4 days of triheptanoin-enriched diet, we observed a correction of end-exercise muscle acidosis -pH at 6.97 and 6.98, Figure 1 -in the two patients with pretreatment metabolic abnormalities (P5 and P6). This was associated with different hyperemic responses after treatment with an earlier return to basal level of perfusion for patient 5 ( Figure 2 ) and the occurrence of a distinct peak of functional hyperemia from the third minute of recovery for patient 6 (Figure 2 ). In addition, we observed a significant increase in serum IGF1 in all HD patients (Table 1) .
DISCUSSION
On the basis of our observation of a hypercatabolic profile early in HD, our short-term study aimed at directly identifying an energy deficit, followed by a therapeutic intervention to improve peripheral energy metabolism in HD patients. Our anaplerotic approach using dietary triheptanoin was well tolerated in all HD patients, both clinically and biochemically. It is noteworthy that the levels of plasma BCAA decreased temporarily after the initiation of triheptanoin before returning to their baseline levels, likely reflecting the reversible inhibition of branched-chain a-ketoacid dehydrogenase kinase by medium-chain fatty acids. 7 Furthermore, we analyzed markers of peripheral energy metabolism that were shown to be altered in early stages of HD, that is, low serum IGF1 1 or delayed phosphocreatine recovery (tPCr) after exercise measured by 31 P-NMR spectroscopy in muscle. 8, 9 Although 31 P-NMR spectroscopy can lack the sensitivity to detect mitochondrial dysfunction, 10 the most noticeable finding from our study was that two patients developed muscle acidosis at baseline while performing a low-intensity exercise. Their end-exercise pH corresponded with W/S ratios three-fold higher than in normal subjects (data not shown). These two patients also had longer tPCrs, but when corrected for pH, tPCrs seemed to be unaltered. 6 This observation differs from previous observations, although endexercise pH was either not reported 8 or unaltered in the HD group. 9 It is noteworthy that our anaplerotic approach with triheptanoin led to a normalization of end-exercise muscle acidosis in the two patients with pretreatment abnormalities. NMR measurements of muscle perfusion also suggested an effect of triheptanoin on hyperemic responses to exercise. Moreover, the improvement in peripheral energy metabolism in our study is supported by the significant increase in serum IGF1 in all HD patients. IGF1 affects mutant huntingtin by promoting its phosphorylation. Phosphorylation inhibits mutant huntingtin toxicity by restoring its transport function. 11, 12 Therefore, the increase in IGF1 after treatment with triheptanoin may exert direct beneficial effects by restoring huntingtin function and/or by blocking huntingtin toxicity in peripheral organs and possibly in the brain. It is not clear how triheptanoin mediates IGF1 levels, especially because triheptanoin did not increase the levels of BCAA -known to regulate IGF1. Ketone bodies cross the blood-brain barrier and ketogenic diet was shown to modulate IGF1 metabolism in the rat brain. 13 Similarly, it would be interesting to assess in vitro whether the ketone bodies derived from triheptanoin -that is, BHP and BKP -can modulate IGF1 levels and huntingtin phosphorylation in primary cultures of striatal neurons.
In addition to the prominent role of brain energy deficit in the pathophysiology of HD, 14, 15 there are several lines of evidence for a more systemic energy deficit. Our findings of hypercatabolism in HD 1 were indeed recently confirmed in both clinical 16, 17 and preclinical studies. 18, 19 Our data emphasize that 31 P-NMRS may provide relevant biomarkers of peripheral energy metabolism in HD. This study also provides a rationale for extending our anaplerotic approach with triheptanoin in HD. A double-blind placebo-controlled trial with Dietary therapy in Huntington disease F Mochel et al clinical outcome measurements is planned to confirm the potential benefit of anaplerotic therapies to improve, or even reverse, the energy deficit both in the periphery and the brain of HD patients and presymptomatic individuals. 
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